Incentives to Enhance Corporate Value through Paid Stock Acquisition Rights Subject to Share Price Conditions
First written in FY2020-Q1. 5 of 7 entries say "Advanced", first in FY2020. Latest entry: 2026-06-29.
0 other companies' latest entry also says "Restated".
- 2026-06-29RestatedFinancial Results Presentation
「These stock options were introduced to seek a strong commitment from officers and employees who joined the company after its business transformation (PIVOT) approximately 7 years ago, toward achieving GMV of ¥100 billion in 2028.」
The company reaffirmed that paid stock options are intended to secure officers' and employees' commitment toward achieving GMV of ¥100 billion in 2028. - FY2026-H1AdvancedAnnual report
「13th series of stock acquisition rights: Number of stock acquisition rights* 3,702; common shares 370,200; exercise period* from 12 December 2025 to 11 December 2030」
The 13th series of stock acquisition rights was issued to the representative director, officers and 23 employees. The plan covers 370,200 shares, has an exercise period from 12 December 2025 to 11 December 2030, and provides staged exercise conditions based on closing share prices of ¥2,600, ¥3,000 and ¥3,600. - FY2025AdvancedAnnual report
「During the current consolidated fiscal year, 229,700 shares under the seventh series of stock options were exercised and 113,400 shares expired. In addition, 10,000 shares under the 10th series of stock options were exercised, leaving an unexercised balance of 239,500 shares at the end of the consolidated fiscal year.」
Specific progress was disclosed for the share price-linked incentives: exercise of 229,700 shares and expiration of 113,400 shares under the seventh series, and exercise of 10,000 shares under the 10th series. - FY2025-H1AdvancedAnnual report
「During the current interim consolidated accounting period, the stock acquisition rights attached to the first series of unsecured convertible bonds with stock acquisition rights, including a conversion price adjustment clause, were converted as follows.」
During the interim period, the convertible bonds with stock acquisition rights resulted in the delivery of 95,067 shares and raised ¥50.000 million in funds. - FY2022-Q2AdvancedAnnual report
「At a meeting of the Board of Directors held on 10 May 2022, we resolved, pursuant to Articles 236, 238 and 240 of the Companies Act, to issue stock acquisition rights as set out below to our representative director, officers and employees, and the officers of our consolidated subsidiaries.」
To support medium- to long-term earnings growth and increased enterprise value, the issuance was approved of 2,500 paid stock acquisition rights covering 250,000 shares, targeted at the representative director, officers, employees and subsidiary officers, with an exercise period from 1 June 2022 to 31 May 2027. Staged exercise conditions based on closing share prices of ¥1,208, ¥1,510 and ¥3,000 were also established. - FY2020AdvancedAnnual report
「Vested (shares) 229,800 / Unvested balance (shares) 113,300 / Unexercised balance (shares) 229,800」
It was disclosed that 229,800 of the 343,100 shares granted under the seventh series of paid stock acquisition rights had vested. - FY2020-Q1First statedAnnual report
「We will issue paid stock acquisition rights to our representative director and the officers of our consolidated subsidiaries as an incentive plan aimed at continuously increasing enterprise value while sharing the benefits and risks associated with the share price with our shareholders, as we seek to improve earnings and increase enterprise value. If all of these stock acquisition rights are exercised, the number of our common shares will increase by 343,100, equivalent to 10% of the total number of issued shares, resulting in a certain degree of dilution for existing shareholders. However, exercise is conditional on the share price reaching predetermined target levels that we aim to achieve.」
An incentive plan involving the first disclosed issuance of paid stock acquisition rights to the representative director and officers of consolidated subsidiaries was disclosed. The plan covers 343,100 shares, equivalent to 10% of total shares issued, with staged exercise conditions requiring the closing share price to exceed 150%, 200% and 250% of the exercise price, and an exercise period from 30 January 2020 to 29 January 2025.